抗腫瘤藥物的高通量篩選-生命科學(xué)試劑-MedChemExpress_第1頁
抗腫瘤藥物的高通量篩選-生命科學(xué)試劑-MedChemExpress_第2頁
抗腫瘤藥物的高通量篩選-生命科學(xué)試劑-MedChemExpress_第3頁
抗腫瘤藥物的高通量篩選-生命科學(xué)試劑-MedChemExpress_第4頁
抗腫瘤藥物的高通量篩選-生命科學(xué)試劑-MedChemExpress_第5頁
已閱讀5頁,還剩5頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Virtual Screening for Anti-tumor Drug Discovery虛擬篩選在抗腫瘤藥物研發(fā)中的應(yīng)用Master of Small Molecules您身邊的抑制劑大師內(nèi)容提要 HTS for Anti-tumor Chemicals 抗腫瘤藥物的高通量篩選 VS for Anti-tumorchemicals 虛擬篩選的應(yīng)用 ToolsforVS 虛擬篩選小工具Cancer 癌癥人類健康殺手Cancer is one of humanitys greatest health challenges.Cancer is the first or second leadi

2、ng cause of death before the age of 70 years in 112 of 183countries and ranks third or fourth in a further 23 countries in 2019.Global cancer statistics 2020. /10.3322/caac.216603MCE Master of Small MoleculesChemicals in cancer treatment 抗腫瘤藥物Chemotherapy and molecularly targeted therapy remain the

3、mainstay for the treatment of cancer Chemotherapy Alkylating agents: Ifosfamide, Arenobufagin, Etoposide Antimetabolite agents: 5-Fluorouracil, 6-Mercaptopurine, Carmofur Targeted therapy Ribociclib/Palbociclib/Abemaciclib:CDK, Cell Cycle/DNA Damage Tivozanib:VEGFR, Protein Tyrosine Kinase/RTK Venet

4、oclax:Bcl-2, Apoptosis/Autophagy Imatinib:BCR/ABL, v-Abl, PDGFR, tyrosine kinases Epacadostat: IDO1 Nolatrexed: TS, Cell CycleMolecules. 2020 Dec 7;25(23):5776.4MCE Master of Small MoleculesScreening Strategies 篩選策略 Target-Based Screening 基于已知靶點(diǎn),篩選出的化合物機(jī)理清楚 篩選范圍明確,得到候選化合物的概率更高 Phenotypic-Based Scree

5、ning 靶點(diǎn)未知,篩出的化合物的作用機(jī)理不清楚 篩選范圍寬泛,需要用大量的化合物進(jìn)行篩選Bioorg Med Chem. 2012 Mar 15;20(6):1922-8.5MCE Master of Small MoleculesDrug Development Process 藥物研發(fā)流程Time-consuming (13-15)High-cost($2.6billion)LowSuccessRate(1/50001/10000)Nat Rev Drug Discov. 2008 Jul;7(7):591-6076MCE Master of Small MoleculesHTS Cas

6、e Study - Discovery of Epacadostat 依帕司他研發(fā)過程EpacadostatDiscovery ofIDO1 inhibitors(IncyteCorporation)Lead optimization Preclinical studys.clinical studys. high throughput screenof300000 compounds; Test absorbance of N- formlylkynurenine in 321nm. Get one lead compound with high potency and selectivit

7、y to IDO1, but with poor oralbioavailability. Synthesization of series ofderivatives(2000compounds). Improve the permeability and oral bioavailability. In vitro & in vivo Biological Assays Pharmacokinetic Assayscombination withantiPD1 mAb,pembrolizumab for thetreatment of patientswith melanoma . Molecularmodelling Enzyme KineticsACS Med. Chem. Lett. 2017, 8, 486-4917MCE Master of Small MoleculesVirtual Screening: Faster, Cheaper虛擬篩選in silico

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論